The evolving role of (131)I for the treatment of differentiated thyroid carcinoma.

The use of radioactive iodine ((131)I) for the treatment of thyroid carcinoma has changed over the past 50 y. These changes are based on increasing awareness of the biophysical properties of (131)I and new discoveries concerning the biology of iodine handling by thyroid cells. The therapeutic administration of (131)I for thyroid remnant ablation and for metastases requires an appreciation of iodine clearance kinetics, of factors that can alter the occupancy time of (131)I within lesions, and of the role of thyroid-stimulating hormone in stimulating the sodium-iodide symporter. The potential complications and adverse events associated with (131)I are discussed. (131)I will continue to be a major weapon in the fight against metastatic thyroid carcinoma. Its future role will be modified by expanding knowledge of its relative risks and benefits.

[1]  M. Schlumberger,et al.  The use of radioactive iodine in patients with papillary and follicular thyroid cancer. , 1998, The Journal of clinical endocrinology and metabolism.

[2]  S. Larson,et al.  Patient-specific dosimetry for 131I thyroid cancer therapy using 124I PET and 3-dimensional-internal dosimetry (3D-ID) software. , 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[3]  P. Fossati,et al.  Is it still worthwhile to treat bone metastases from differentiated thyroid carcinoma with radioactive iodine? , 1992, World Journal of Surgery.

[4]  A. Oberg,et al.  Papillary Thyroid Carcinoma Managed at the Mayo Clinic during Six Decades (1940–1999): Temporal Trends in Initial Therapy and Long-term Outcome in 2444 Consecutively Treated Patients , 2002, World Journal of Surgery.

[5]  M. Tubiana,et al.  [Results of examination of 85 cases of cancer of the thyroid with radioactive iodine]. , 1951, Journal de radiologie, d'electrologie & archives d'electricite medicale.

[6]  A. Pinchera,et al.  Exposure to radioactive iodine-131 for scintigraphy or therapy does not preclude pregnancy in thyroid cancer patients. , 1996, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[7]  Y. Yoshimoto.  Cancer Risk Among Children of Atomic Bomb Survivors: A Review of RERF Epidemiologic Studies , 1990 .

[8]  M. Dottorini,et al.  Differentiated thyroid carcinoma in children and adolescents: a 37-year experience in 85 patients. , 1997, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[9]  J. Shah,et al.  Prognostic indicators of outcomes in patients with distant metastases from differentiated thyroid carcinoma. , 2003, Journal of the American College of Surgeons.

[10]  H. Griesser,et al.  Increased I-131 uptake in local recurrence and distant metastases after second treatment with retinoic acid. , 1999, Clinical nuclear medicine.

[11]  P. Hall,et al.  Second primary malignancies in thyroid cancer patients , 2003, British Journal of Cancer.

[12]  M. Schlumberger,et al.  Circulating thyroglobulin and thyroid hormones in patients with metastases of differentiated thyroid carcinoma: relationship to serum thyrotropin levels. , 1980, The Journal of clinical endocrinology and metabolism.

[13]  M. Tubiana,et al.  [Disappearance of pulmonary metastases of a thyroid cancer under the action of radioactive iodine 131]. , 1951, Journal de radiologie, d'electrologie & archives d'electricite medicale.

[14]  S. Mandel,et al.  Radioactive iodine and the salivary glands. , 2003, Thyroid : official journal of the American Thyroid Association.

[15]  M. Tubiana,et al.  [Problems of dosimetry posed by the utilization of radioactive iodine in the treatment of cancer of the thyroid]. , 1954, Journal de radiologie, d'electrologie & archives d'electricite medicale.

[16]  E. Bergstralh,et al.  Distant metastases in differentiated thyroid carcinoma: a multivariate analysis of prognostic variables. , 1988, The Journal of clinical endocrinology and metabolism.

[17]  C. Villabona,et al.  Blood volumes and renal function in overt and subclinical primary hypothyroidism. , 1999, The American journal of the medical sciences.

[18]  B. Caillou,et al.  Long-term results of treatment of 283 patients with lung and bone metastases from differentiated thyroid carcinoma. , 1986, The Journal of clinical endocrinology and metabolism.

[19]  S. Larson,et al.  A retrospective review of the effectiveness of recombinant human TSH as a preparation for radioiodine thyroid remnant ablation. , 2002, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[20]  S. Larson,et al.  Bone metastases from thyroid carcinoma: clinical characteristics and prognostic variables in one hundred forty-six patients. , 2000, Thyroid : official journal of the American Thyroid Association.

[21]  David Handelsman,et al.  TESTICULAR DAMAGE AFTER RADIOACTIVE IODINE (I‐131) THERAPY FOR THYROID CANCER , 1983, Clinical endocrinology.

[22]  S. Jhiang,et al.  Nasolacrimal Obstruction Secondary to I131 Therapy , 2004, Ophthalmic plastic and reconstructive surgery.

[23]  A. De la Vieja,et al.  Molecular analysis of the sodium/iodide symporter: impact on thyroid and extrathyroid pathophysiology. , 2000, Physiological reviews.

[24]  B. Jarzab,et al.  Recombinant human TSH-aided radioiodine treatment of advanced differentiated thyroid carcinoma: a single-centre study of 54 patients , 2003, European Journal of Nuclear Medicine and Molecular Imaging.

[25]  S. Filetti,et al.  Expression pattern of the pendrin and sodium/iodide symporter genes in human thyroid carcinoma cell lines and human thyroid tumors. , 2001, European journal of endocrinology.

[26]  M. Luster,et al.  Impact of 131I diagnostic activities on the biokinetics of thyroid remnants. , 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[27]  M. Tubiana,et al.  [The survival of patients with thyroid cancers treated with radioactive iodine. Apropos of 147 cases followed up for more than 5 years]. , 1968, La Presse medicale.

[28]  A. Pinchera,et al.  Therapeutic doses of iodine-131 reveal undiagnosed metastases in thyroid cancer patients with detectable serum thyroglobulin levels. , 1987, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[29]  E. Baudin,et al.  Is diagnostic iodine-131 scanning useful after total thyroid ablation for differentiated thyroid cancer? , 2000, The Journal of clinical endocrinology and metabolism.

[30]  G. Masarotto,et al.  Different features of pulmonary metastases in differentiated thyroid cancer: natural history and multivariate statistical analysis of prognostic variables. , 1993, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[31]  A. Pinchera,et al.  Testicular function in patients with differentiated thyroid carcinoma treated with radioiodine. , 1994, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[32]  M. Luster,et al.  Comparison of radioiodine biokinetics following the administration of recombinant human thyroid stimulating hormone and after thyroid hormone withdrawal in thyroid carcinoma , 2003, European Journal of Nuclear Medicine and Molecular Imaging.

[33]  C. Schmutzler.  Regulation of the sodium/iodide symporter by retinoids--a review. , 2001, Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association.

[34]  G. Wiseman,et al.  Lack of impact of radioiodine therapy in tg-positive, diagnostic whole-body scan-negative patients with follicular cell-derived thyroid cancer. , 2002, The Journal of clinical endocrinology and metabolism.

[35]  V S Hertzberg,et al.  Radioiodine-131 therapy for well-differentiated thyroid cancer--a quantitative radiation dosimetric approach: outcome and validation in 85 patients. , 1992, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[36]  R. Kloos,et al.  The Journal of Clinical Endocrinology & Metabolism Printed in U.S.A. Copyright © 2001 by The Endocrine Society CLINICAL REVIEW 128 Current Approaches to Primary Therapy for Papillary , 2022 .

[37]  Keitaro Tanaka,et al.  Second Primary Neoplasms in Thyroid Cancer Patients , 1996, Japanese journal of cancer research : Gann.

[38]  M. Schlumberger,et al.  Biological dosimetry in patients treated with iodine-131 for differentiated thyroid carcinoma. , 1996, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[39]  A. Pinchera,et al.  Prediction of disease status by recombinant human TSH-stimulated serum Tg in the postsurgical follow-up of differentiated thyroid carcinoma. , 2001, The Journal of clinical endocrinology and metabolism.

[40]  E. Baudin,et al.  Combination of radioiodine (131I) and probe-guided surgery for persistent or recurrent thyroid carcinoma. , 1998, The Journal of clinical endocrinology and metabolism.

[41]  J. Raymond,et al.  Temporary ovarian failure in thyroid cancer patients after thyroid remnant ablation with radioactive iodine. , 1989, The Journal of clinical endocrinology and metabolism.

[42]  M. Schlumberger,et al.  Radioactive iodine treatment and external radiotherapy for lung and bone metastases from thyroid carcinoma. , 1996, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[43]  H. Gharib,et al.  AACE/AAES medical/surgical guidelines for clinical practice: management of thyroid carcinoma. American Association of Clinical Endocrinologists. American College of Endocrinology. , 2001, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

[44]  V S Hertzberg,et al.  Relation between effective radiation dose and outcome of radioiodine therapy for thyroid cancer. , 1983, The New England journal of medicine.

[45]  S. Larson,et al.  [18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography localizes residual thyroid cancer in patients with negative diagnostic (131)I whole body scans and elevated serum thyroglobulin levels. , 1999, The Journal of clinical endocrinology and metabolism.

[46]  B. Weintraub,et al.  A comparison of recombinant human thyrotropin and thyroid hormone withdrawal for the detection of thyroid remnant or cancer. , 1999, The Journal of clinical endocrinology and metabolism.

[47]  T. Endo,et al.  Histone deacetylase inhibitors restore radioiodide uptake and retention in poorly differentiated and anaplastic thyroid cancer cells by expression of the sodium/iodide symporter thyroperoxidase and thyroglobulin. , 2004, Endocrinology.

[48]  S. Larson,et al.  Radioiodine ablation of thyroid remnants after preparation with recombinant human thyrotropin. , 2001, Thyroid : official journal of the American Thyroid Association.

[49]  M. Dottorini,et al.  Assessment of female fertility and carcinogenesis after iodine-131 therapy for differentiated thyroid carcinoma. , 1995, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[50]  I. Hay,et al.  Managing patients with papillary thyroid carcinoma: insights gained from the Mayo Clinic's experience of treating 2,512 consecutive patients during 1940 through 2000. , 2002, Transactions of the American Clinical and Climatological Association.

[51]  S. Larson,et al.  Resistance of [18f]-fluorodeoxyglucose-avid metastatic thyroid cancer lesions to treatment with high-dose radioactive iodine. , 2001, Thyroid : official journal of the American Thyroid Association.

[52]  E. Mazzaferri.  Treating high thyroglobulin with radioiodine: a magic bullet or a shot in the dark? , 1995, The Journal of clinical endocrinology and metabolism.

[53]  L. Duntas,et al.  Follow-up of low-risk patients with differentiated thyroid carcinoma: a European perspective. , 2004, European journal of endocrinology.

[54]  S. Filetti,et al.  Expression of nicotinamide adenine dinucleotide phosphate oxidase flavoprotein DUOX genes and proteins in human papillary and follicular thyroid carcinomas. , 2001, Thyroid : official journal of the American Thyroid Association.

[55]  E. Baudin,et al.  131I therapy for elevated thyroglobulin levels. , 1997, Thyroid : official journal of the American Thyroid Association.

[56]  E. Baudin,et al.  Positive predictive value of serum thyroglobulin levels, measured during the first year of follow-up after thyroid hormone withdrawal, in thyroid cancer patients. , 2003, The Journal of clinical endocrinology and metabolism.

[57]  Stephanie L. Lee,et al.  A consensus report of the role of serum thyroglobulin as a monitoring method for low-risk patients with papillary thyroid carcinoma. , 2003, The Journal of clinical endocrinology and metabolism.

[58]  T. Petrich,et al.  Influence of rhTSH on [(18)F]fluorodeoxyglucose uptake by differentiated thyroid carcinoma. , 2002, European journal of nuclear medicine and molecular imaging.

[59]  M. Schlumberger,et al.  The risk of multiple primary breast and thyroid carcinomas , 2003, Cancer.

[60]  A. Pinchera,et al.  131I therapy for differentiated thyroid cancer leads to an earlier onset of menopause: Results of a retrospective study , 2002 .

[61]  G. Daniels,et al.  Radioactive iodine lobe ablation as an alternative to completion thyroidectomy for follicular carcinoma of the thyroid. , 2002, Thyroid : official journal of the American Thyroid Association.

[62]  Heno . Nevotlo.  Papillary Thyroid Carcinoma: A 10 Year Follow-Up Report of the Impact of Therapy in 576 Patients , 1981 .

[63]  G. Reischl,et al.  Evaluation of dosimetry of radioiodine therapy in benign and malignant thyroid disorders by means of iodine-124 and PET , 2002, European Journal of Nuclear Medicine and Molecular Imaging.

[64]  S. Gulec,et al.  Dosimetry-guided radioactive iodine treatment in patients with metastatic differentiated thyroid cancer: largest safe dose using a risk-adapted approach. , 2003, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[65]  M. Sonenberg,et al.  The relation of radioiodine dosimetry to results and complications in the treatment of metastatic thyroid cancer. , 1962, The American journal of roentgenology, radium therapy, and nuclear medicine.

[66]  A. Pinchera,et al.  Outcome of differentiated thyroid cancer with detectable serum Tg and negative diagnostic (131)I whole body scan: comparison of patients treated with high (131)I activities versus untreated patients. , 2001, The Journal of clinical endocrinology and metabolism.

[67]  M. Hawkins.  Is there evidence of a therapy-related increase in germ cell mutation among childhood cancer survivors? , 1991, Journal of the National Cancer Institute.

[68]  V. R. McCready,et al.  Radiation dose assessment in radioiodine therapy. Dose-response relationships in differentiated thyroid carcinoma using quantitative scanning and PET. , 1993, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[69]  F. Miot,et al.  Correlation between the loss of thyroglobulin iodination and the expression of thyroid-specific proteins involved in iodine metabolism in thyroid carcinomas. , 2003, The Journal of clinical endocrinology and metabolism.

[70]  C. Bal,et al.  Radioiodine dose for remnant ablation in differentiated thyroid carcinoma: a randomized clinical trial in 509 patients. , 2004, The Journal of clinical endocrinology and metabolism.

[71]  M. Dempsey,et al.  Self-stunning in thyroid ablation: evidence from comparative studies of diagnostic 131I and 123I , 2002, European Journal of Nuclear Medicine and Molecular Imaging.

[72]  G. Zettinig,et al.  Long‐term follow‐up of patients with bone metastases from differentiated thyroid carcinoma – surgery or conventional therapy? , 2002, Clinical endocrinology.

[73]  S. Jhiang,et al.  Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. , 1994, The American journal of medicine.

[74]  H. Gerstein,et al.  Clinical review 170: A systematic review and metaanalysis of the effectiveness of radioactive iodine remnant ablation for well-differentiated thyroid cancer. , 2004, The Journal of clinical endocrinology and metabolism.

[75]  C. Glanzmann.  Subsequent malignancies in patients treated with 131-iodine for thyroid cancer. , 1992, Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al].

[76]  P. Hall,et al.  Cancer risks in thyroid cancer patients. , 1991, British Journal of Cancer.

[77]  E. Hindié,et al.  Functioning pulmonary metastases of thyroid cancer: does radioiodine influence the prognosis? , 2003, European Journal of Nuclear Medicine and Molecular Imaging.

[78]  F. Cetani,et al.  Outcome of 309 patients with metastatic differentiated thyroid carcinoma treated with radioiodine , 1994, World Journal of Surgery.

[79]  E. D. de Vries,et al.  Better yield of (18)fluorodeoxyglucose-positron emission tomography in patients with metastatic differentiated thyroid carcinoma during thyrotropin stimulation. , 2002, Thyroid : official journal of the American Thyroid Association.

[80]  Y. Yoshimoto.  Cancer risk among children of atomic bomb survivors. A review of RERF epidemiologic studies , 1991, JAMA.

[81]  M. Sonenberg,et al.  An 18 Year Study of the Use of Beef Thyrotropin to Increase I131 Uptake in Metastatic Thyroid Cancer , 1964 .

[82]  B. Haugen,et al.  Retinoic acid and retinoid X receptors are differentially expressed in thyroid cancer and thyroid carcinoma cell lines and predict response to treatment with retinoids. , 2004, The Journal of clinical endocrinology and metabolism.

[83]  A. Pinchera,et al.  Diagnostic 131-iodine whole-body scan may be avoided in thyroid cancer patients who have undetectable stimulated serum Tg levels after initial treatment. , 2002, The Journal of clinical endocrinology and metabolism.

[84]  K. Ain,et al.  Lithium as a potential adjuvant to 131I therapy of metastatic, well differentiated thyroid carcinoma. , 1999, The Journal of clinical endocrinology and metabolism.

[85]  Amy Y. Chen,et al.  The development of breast carcinoma in women with thyroid carcinoma , 2001, Cancer.

[86]  A. Chakravarti,et al.  Normal findings 52 years after in utero radiation exposure , 1991, The Lancet.

[87]  S. M. Seidlin,et al.  Spontaneous and experimentally induced uptake of radioactive iodine in metastases from thyroid carcinoma; a preliminary report. , 1948, The Journal of clinical endocrinology and metabolism.

[88]  P. Ladenson,et al.  Treatment guidelines for patients with thyroid nodules and well-differentiated thyroid cancer. American Thyroid Association. , 1996, Archives of internal medicine.